Verrica Pharmaceuticals Inc. 10-K

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASE OF EQUITY SECURITIES Dividend Policy We have never declared or paid, and do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. Pursuant to the Loan Agreements, we are also restricted from paying dividends or making other distributions or payments on our capital stock, subject to limited exceptions. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant . Stockholders Our common stock is listed on the Nasdaq Global Select Market under the symbol “VRCA”. As of March 15 , 2021, we had 25,441,113 shares of common stock outstanding held by 32 holders of record. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities. Use of Proceeds from Initial Public Offering of Common Stock Not applicable. Recent Sales of Unregistered Securities None. Purchases of Equity Securities by the Issuer and Affiliated Parties The following table summarizes repurchases of our common stock during December 2020. There were no purchases during October 2020 or November 2020. Total Number of Shares Average Price Paid per Total Number of Shares Purchased as Part of a Publicly Approximate Dollar Value of Shares that May Yet be Purchased Period Purchased Share Announced Program Under the Program 12/1/2020 - 12/31/2020 424,429 (1) $ 0.0001714 — $ — (1) These shares of common stock were repurchased from our former Chief Scientific Officer pursuant to a restricted stock purchase agreement, as amended. ITEM 6. SELECTED FINANCIAL DATA Not applicable. 74